RCROT02 – Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19 – Project Plan now available
EUnetHTA is pleased to announce the publication of the final project plan of its Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19. This is the second one of
To help in the development of a coordinated response to the Covid-19 pandemic, it is essential that researched, timely and reliable information can be made available to all stakeholders, whether healthcare professionals or members of the public. With this in mind,
We are pleased to publish the Autumn 2019 issue of EUnetHTA Magazine. Intended for improved accessibility on whichever device you use, this issue includes various contributions from the EUnetHTA member network, while updating information on EUnetHTA products and the state
PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active